Ginkgo Bioworks Holdings, Inc.
DNA
$6.79
-$0.45-6.22%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 111.86M | 130.84M | 149.60M | 160.05M | 210.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 111.86M | 130.84M | 149.60M | 160.05M | 210.26M |
| Cost of Revenue | 24.92M | 28.58M | 29.57M | 31.89M | 31.10M |
| Gross Profit | 86.94M | 102.26M | 120.02M | 128.15M | 179.16M |
| SG&A Expenses | 158.47M | 167.40M | 171.51M | 177.48M | 184.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 399.00M | 418.75M | 444.86M | 479.40M | 493.59M |
| Operating Income | -287.13M | -287.91M | -295.26M | -319.35M | -283.33M |
| Income Before Tax | -295.48M | -291.76M | -298.85M | -325.31M | -301.34M |
| Income Tax Expenses | -594.00K | -1.01M | -837.00K | -519.00K | -895.00K |
| Earnings from Continuing Operations | -294.89 | -290.76 | -298.01 | -324.79 | -300.44 |
| Earnings from Discontinued Operations | 4.08M | -13.63M | -14.75M | -14.75M | -14.75M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -290.80M | -304.39M | -312.76M | -339.55M | -315.19M |
| EBIT | -287.13M | -287.91M | -295.26M | -319.35M | -283.33M |
| EBITDA | -252.89M | -250.73M | -256.06M | -278.16M | -238.44M |
| EPS Basic | -5.00 | -5.35 | -5.64 | -6.23 | -5.85 |
| Normalized Basic EPS | -2.91 | -2.93 | -3.04 | -3.36 | -2.91 |
| EPS Diluted | -5.01 | -5.36 | -5.65 | -6.23 | -5.85 |
| Normalized Diluted EPS | -2.91 | -2.93 | -3.04 | -3.36 | -2.91 |
| Average Basic Shares Outstanding | 234.37M | 227.14M | 221.82M | 218.55M | 215.16M |
| Average Diluted Shares Outstanding | 234.37M | 227.14M | 221.82M | 218.55M | 215.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |